Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories diagnostics — Segment Research & Development Expense ($M) ($M)
Form 10-K / 10-Q Segment Footnote
Latest, Q2 2026
268
Period ended Jun 30, 2026
Change on a year earlier
+74.0%
154 in Q2 2025
History
10 quarters
Since Q1 2024
Sources
6
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Diagnostics — Segment Research & Development Expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 268 | +74.0% | SEC Filing (0001628280-26-050134) ↗ |
| Q1 2026 | Mar 31, 2026 | 155 | +2.6% | SEC Filing (0001628280-26-028357) ↗ |
| Q4 2025 | Dec 31, 2025 | 147 | -15.5% | SEC Filing (0001628280-26-010185) ↗ |
| Q3 2025 | Sep 30, 2025 | 150 | -9.1% | SEC Filing (0001628280-25-047131) ↗ |
| Q2 2025 | Jun 30, 2025 | 154 | -4.9% | SEC Filing (0001628280-26-050134) ↗ |
| Q1 2025 | Mar 31, 2025 | 151 | -2.6% | SEC Filing (0001628280-26-028357) ↗ |
| Q4 2024 | Dec 31, 2024 | 174 | – | SEC Filing (0001628280-26-010185) ↗ |
| Q3 2024 | Sep 30, 2024 | 165 | – | SEC Filing (0001628280-25-047131) ↗ |
| Q2 2024 | Jun 30, 2024 | 162 | – | SEC Filing (0001628280-25-036720) ↗ |
| Q1 2024 | Mar 31, 2024 | 155 | – | SEC Filing (0001628280-25-021090) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories Diagnostics — Segment Research & Development Expense ($M) ($M), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-rd-exp
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.